[go: up one dir, main page]

AR039464A1 - Composiciones farmaceuticas de liberacion controlada, extendida que usan polimeros cargados - Google Patents

Composiciones farmaceuticas de liberacion controlada, extendida que usan polimeros cargados

Info

Publication number
AR039464A1
AR039464A1 ARP030101458A ARP030101458A AR039464A1 AR 039464 A1 AR039464 A1 AR 039464A1 AR P030101458 A ARP030101458 A AR P030101458A AR P030101458 A ARP030101458 A AR P030101458A AR 039464 A1 AR039464 A1 AR 039464A1
Authority
AR
Argentina
Prior art keywords
polymer
treatment agent
ionic
extended
agent
Prior art date
Application number
ARP030101458A
Other languages
English (en)
Inventor
Howard L Levine
William J Bologna
Original Assignee
Columbia Lab Bermuda Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/278,912 external-priority patent/US20030114394A1/en
Application filed by Columbia Lab Bermuda Ltd filed Critical Columbia Lab Bermuda Ltd
Publication of AR039464A1 publication Critical patent/AR039464A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A61K31/245—Amino benzoic acid types, e.g. procaine, novocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Reproductive Health (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Inorganic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pregnancy & Childbirth (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Composición farmacéutica bioadhesiva que comprende un agente de tratamiento iónico y un polímero iónico, en donde el polímero está suficientemente ionizado para proporcionar la unión con el agente de tratamiento para permitir que la composición libere el agente de tratamiento en una forma controlada durante un período de tiempo extendido y en donde la composición no requiere un sistema de emulsión para administrar el agente de tratamiento. Dicho polímero es un polímero de ácido policarboxílico entrecruzado bioadhesivo, que puede hincharse en agua y el agente de tratamiento es un agente de tratamiento catiónico, que incluye uno o más de amitriptilina, amantadina, y otros de acuerdo con la memoria. Cuando el agente de tratamiento es un compuesto aniónico, éste se selecciona entre uno o más de naproxeno, fenobarbital y otros de acuerdo con la memoria. Uso de un agente de tratamiento iónico y de un polímero iónico para la fabricación de una composición farmacéutica para el tratamiento, prevención del dolor pélvico o para tratar o mejorar la infertilidad.
ARP030101458A 2002-10-24 2003-04-28 Composiciones farmaceuticas de liberacion controlada, extendida que usan polimeros cargados AR039464A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/278,912 US20030114394A1 (en) 2001-10-29 2002-10-24 Vaginally administered anti-dysrhythmic agents for treating pelvic pain
US43850103P 2003-01-08 2003-01-08

Publications (1)

Publication Number Publication Date
AR039464A1 true AR039464A1 (es) 2005-02-23

Family

ID=32179474

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP030101458A AR039464A1 (es) 2002-10-24 2003-04-28 Composiciones farmaceuticas de liberacion controlada, extendida que usan polimeros cargados

Country Status (23)

Country Link
EP (1) EP1556015B1 (es)
JP (1) JP5204374B2 (es)
KR (1) KR20050083802A (es)
CN (2) CN101327326A (es)
AR (1) AR039464A1 (es)
AU (1) AU2003233066B2 (es)
BR (1) BR0315576A (es)
CA (1) CA2503383C (es)
CO (1) CO5700711A2 (es)
ES (1) ES2618300T3 (es)
HR (1) HRP20050448A2 (es)
MA (1) MA27493A1 (es)
ME (2) MEP34108A (es)
MX (1) MXPA05004330A (es)
NO (1) NO20052480L (es)
NZ (1) NZ539512A (es)
PE (2) PE20081613A1 (es)
PL (1) PL376537A1 (es)
RS (1) RS20050321A (es)
RU (2) RU2366410C2 (es)
TW (1) TW200406223A (es)
WO (1) WO2004037229A1 (es)
ZA (1) ZA200503133B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1888038A2 (en) * 2005-05-10 2008-02-20 Novartis AG Modified release famciclovir pharmaceutical compositions
WO2017130208A1 (en) * 2016-01-29 2017-08-03 Faheem Hyder Pottoo Triple drug combination for treatment of status epilepticus and/or partial seizures and/or partial seizures with associated neurological disorders
CN119074731A (zh) * 2024-09-20 2024-12-06 湖南师范大学 盐酸达克罗宁在预防雌性小鼠下丘脑-垂体-卵巢轴损伤中的应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0830004B2 (ja) * 1983-11-14 1996-03-27 コロンビア ラボラトリーズ インコーポレイテッド 生物接着性組成物およびそれにより治療する方法
ES2050096T3 (es) * 1989-10-31 1995-01-16 Columbia Lab Inc Composicion humidificante del tejido vaginal.
IL114589A (en) * 1990-11-21 1999-12-22 Roussel Uclaf Intermediates for the preparation of erythromycin derivatives
US5578315A (en) * 1993-12-01 1996-11-26 Rutgers, The State University Of New Jersey Mucosal adhesive device for long-acting delivery of pharmaceutical combinations in oral cavity
ZA951877B (en) * 1994-03-07 1996-09-09 Dow Chemical Co Bioactive and/or targeted dendrimer conjugates
US5667492A (en) * 1994-10-07 1997-09-16 Columbia Laboratories, Inc. Use and composition of an anti-sexually transmitted diseases formulation
US6197327B1 (en) * 1997-06-11 2001-03-06 Umd, Inc. Device and method for treatment of dysmenorrhea
DE69819748T2 (de) * 1997-09-12 2004-09-30 Columbia Laboratories (Bermuda) Ltd. Arzneimittel zur behandlung von dysmenorrhöe und verfrühten wehen
US6624200B2 (en) * 1998-08-25 2003-09-23 Columbia Laboratories, Inc. Bioadhesive progressive hydration tablets
US6248358B1 (en) * 1998-08-25 2001-06-19 Columbia Laboratories, Inc. Bioadhesive progressive hydration tablets and methods of making and using the same
UA74168C2 (uk) * 1999-10-05 2005-11-15 Коламбіа Леборетеріс (Бермуда) Лімітед Лікування ендометріозу або безпліддя, або покращення плідності та застосування бета-адренергічного агоніста для виробництва лікарського засобу

Also Published As

Publication number Publication date
AU2003233066A1 (en) 2004-05-13
RU2009112072A (ru) 2010-10-10
ES2618300T3 (es) 2017-06-21
WO2004037229A1 (en) 2004-05-06
JP5204374B2 (ja) 2013-06-05
TW200406223A (en) 2004-05-01
NO20052480D0 (no) 2005-05-23
RS20050321A (sr) 2007-08-03
NZ539512A (en) 2009-03-31
KR20050083802A (ko) 2005-08-26
CN1703205A (zh) 2005-11-30
ME00233B (me) 2011-05-10
BR0315576A (pt) 2005-08-30
AU2003233066B2 (en) 2009-11-19
HRP20050448A2 (en) 2005-12-31
CA2503383C (en) 2013-03-12
EP1556015A1 (en) 2005-07-27
CO5700711A2 (es) 2006-11-30
RU2366410C2 (ru) 2009-09-10
PL376537A1 (pl) 2006-01-09
NO20052480L (no) 2005-07-25
ZA200503133B (en) 2006-12-27
JP2006506453A (ja) 2006-02-23
PE20040323A1 (es) 2004-06-10
CN1703205B (zh) 2010-12-01
MXPA05004330A (es) 2005-08-02
EP1556015B1 (en) 2017-02-22
CA2503383A1 (en) 2004-05-06
PE20081613A1 (es) 2008-11-15
MEP34108A (hr) 2011-02-10
MA27493A1 (fr) 2005-08-01
CN101327326A (zh) 2008-12-24
RU2005115574A (ru) 2005-10-27

Similar Documents

Publication Publication Date Title
MA27523A1 (fr) Formulation retard a liberation controlee
AR063621A1 (es) Matriz polimerica insoluble en agua para la administracion de farmacos
CY1114646T1 (el) Τοπικα συστηματα παροχης γελης για την θεραπευτικη αντιμετωπιση των διαταραχων δερματος
BR0009213A (pt) Processos e composições para tratamento de tumores sólidos
CY1107512T1 (el) Νεες υποκατεστημενες με βενζιμιδαζολιο μορφες δοσολογιας και μεθοδος για τη χρηση τους
DE60118933D1 (de) Matrix zur aufnahme von arzneimitteln
PT1053746E (pt) Utilizacao de micro-esferas biodegradaveis libertando um agente anticanceroso para o tratamento do glioblastoma
BRPI0811948B8 (pt) novo agente para a liberação de princípios ativos em curativos que contenham ao menos uma susbtância gordurosa
ES2557988T3 (es) Método para tratar enfermedades de próstata basado en el suministro local de principios activos
GT199900151A (es) Sistema de entrega controlado de droga administrado oralmente, que provee control temporal y espacial.
ATE460164T1 (de) Mittel zur behandlung von hyperlipidämie mit pitavastatinen und eicosapentaensäure
ATE310542T1 (de) Beschichtete implantate
CL2004000409A1 (es) Compuestos derivados de 2-(cilo sustituido)-1-(amino u oxi sustituido)-quinazolina, inhibidores de canales ionicos de sodio y calcio dependientes de voltaje; composicion farmaceutica; y uso del compuesto en el tratamiento de dolor agudo, cronico, neu
BRPI0510925A (pt) métodos e composições para cicatrização de ferida
SE0004671D0 (sv) Pharmaceutical formulation
RU2010153904A (ru) Ниацин-содержащие композиции с модифицированным высвобождением
DK1345595T3 (da) Ionstyrke-uafhængig farmaceutisk formulering med depotfrigivelse
BR0016071B1 (pt) método para inibir polimerização prematura de monÈmeros etilenicamente insaturados e composição.
BR9910678A (pt) Composto, composição farmacêutica, método para traramento ou prevenção de uma doença inflamatória, método para tratamento de uma condição ou uma doença mediada por mmps, tnf, agrecanase, ou um composto dos mesmos, em um mamìfero, método de redução de nìveis de tnf em pacientes, sem a inibição de mmps, método para tratamento de uma condição ou uma doença e uso de um novo composto
AR039464A1 (es) Composiciones farmaceuticas de liberacion controlada, extendida que usan polimeros cargados
AR004315A1 (es) Composicion que comprende el producto precipitado en la mezcla de una sal metalica soluble y uno o mas compuestos que tienen un componente seleccionadode silicatos, fosfatos o boratos y metodo para el control de drenaje y/o retencion de agua en la formacion de una matriz de papel y para el tratamiento
ES2180729T3 (es) Tratamiento terapeutico combinado de las patologias hiperproliferantes.
MX2007000418A (es) Metodos y reactivos para tratar abejas para acaros parasiticos.
MXPA04006418A (es) Composicion que comprende por lo menos una oxazolina para inhibir la migracion de celulas de langerhans y usos de la misma.
BR0111504A (pt) Composições dilatáveis em água

Legal Events

Date Code Title Description
FA Abandonment or withdrawal
FC Refusal